Exhibit 99.1

	AutoImmune Inc.
	1199 Madia Street
	Pasadena, CA 91103
	Phone: 626-792-1235
	Fax: 626-792-1236

Contact:

Robert C. Bishop, Ph.D.

Chairman and Chief Executive Officer

AutoImmune Inc.

626-792-1235

website: http://www.autoimmuneinc.com

FOR IMMEDIATE RELEASE

AUTOIMMUNE INC. REPORTS 2007 THIRD QUARTER FINANCIAL RESULTS

Pasadena, California, November 8, 2007—AutoImmune Inc. (OTCBB: AIMM) today reported a net loss of $8,000, or break even per share basic and diluted, for the three months ended September 30, 2007, compared with a net loss of $36,000, or break even per share basic and diluted, for the three months ended September 30, 2006. For the nine months ended September 30, 2007, the net loss was $62,000, or break even per share basic and diluted, compared with net loss of $517,000, or $0.03 per share basic and diluted for the same period in 2006. As of September 30, 2007, the Company reported $8.7 million in cash and marketable securities as compared to $8.8 million in cash and marketable securities as of December 31, 2006.

Chairman of the Board and Chief Executive Officer Robert C. Bishop, Ph.D. stated, “Product sales at Colloral LLC, our joint venture with Deseret Laboratories, Inc., were disappointing in the quarter just ended, but we remain optimistic they will increase in coming months. While sales through GNC have ceased, Bronson Laboratories LLC is selling the product through its catalogs, and Colloral LLC began marketing the product through The Shopping Channel in Canada in early October.” AutoImmune consolidates Colloral LLC for financial reporting purposes in accordance with FIN 46 “Consolidation of Variable Interest Entities.”

AutoImmune has exclusively licensed certain of its intellectual property rights to BioMS Medical Corp., a Canadian company. Under the license agreement, BioMS makes monthly diligence payments to AutoImmune and will pay royalties to AutoImmune on sales of its lead drug MBP8298, if it reaches the market. BioMS recently reported that 70% of the patients screened for their first pivotal trial in secondary multiple sclerosis have the HLA-DR2/DR4 genes that are believed to make them responsive to therapy with MBP8298. Interim results from this trial are expected in May 2008.

AutoImmune is a biopharmaceutical company involved in the development of a new class of mucosally administered therapies for the treatment of autoimmune and cell-mediated inflammatory diseases and conditions.

This release contains forward-looking statements that involve risks and uncertainties. The Company’s actual results may differ significantly from results discussed in the forward-looking statements due to a number of important factors, including, but not limited to the uncertainties of clinical trial results, the Company’s dependence on third parties for licensing revenue, and the risks of technological change and competition. These factors are more fully discussed in the Company’s most recent Annual Report on Form 10-KSB filed with the Securities and Exchange Commission in the section “Risk Factors” The discussion in the Annual Report on Form 10-KSB is hereby referenced into this release.

- Financial Chart Follows -

AUTOIMMUNE INC.

STATEMENT OF OPERATIONS

(Unaudited)

	Three months ended September 30,						Nine months ended September 30,
	2006			2007			2006			2007
Revenue	$	80,000		$	59,000		$	264,000		$	219,000
Costs and expenses:
Cost of product revenue		5,000			9,000			18,000			20,000
Research and development		25,000			7,000			172,000			95,000
Selling, general and administrative		199,000			163,000			906,000			526,000
Total costs and expenses		229,000			179,000			1,096,000			641,000
Interest income		113,000			112,000			315,000			335,000
Other income		—			—			—			25,000
		113,000			112,000			315,000			360,000
Net loss	$	(36,000	)	$	(8,000	)	$	(517,000	)	$	(62,000	)
Net loss per share—basic	$	(0.00	)	$	(0.00	)	$	(0.03	)	$	(0.00	)
Net loss per share—diluted	$	(0.00	)	$	(0.00	)	$	(0.03	)	$	(0.00	)
Weighted average common shares outstanding—basic		16,919,623			16,979,623			16,919,623			16,967,504
Weighted average common shares outstanding—diluted		16,919,623			16,979,623			16,919,623			16,967,504

CONDENSED BALANCE SHEET

(Unaudited)

	December 31, 2006		September 30, 2007
Cash and marketable securities	$	8,763,000	$	8,692,000
Other current assets		188,000		311,000
Total assets	$	8,951,000	$	9,003,000
Current liabilities	$	128,000	$	149,000
Total stockholders’ equity		8,823,000		8,854,000
Total liabilities and equity	$	8,951,000	$	9,003,000